3 recruiting, 1 completed, 1 not yet recruiting, 1 withdrawn. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow Ellipses Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Tolerability of EP0089 EP0089-101 - Solid Cancers, Solid Tumours | Phase 1 / Phase 2 | Not yet recruiting | Ellipses Pharma | 190 | 2025-09-01 | 2025-06-22 |
| EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer EP0057, Olaparib tablets - Gastric Cancer, Small-cell Lung Cancer | Phase 2 | Withdrawn | Ellipses Pharma | 2023-04-01 | 2023-06-12 | |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 95 | 2023-01-11 | 2026-06-22 |
| A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies EP0031, Platinum chemotherapy, Pemetrexed - NSCLC | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 265 | 2022-09-30 | 2026-07-01 |
| EP0057 in Combination With Olaparib in Advanced Ovarian Cancer EP0057, Olaparib tablets - Ovarian Cancer | Phase 2 | Completed | Ellipses Pharma | 34 | 2020-12-14 | 2023-08-02 |
| Study to Evaluate the Safety and Tolerability of EP0042 EP0042, Venetoclax, Azacitidine (AZA) - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Ellipses Pharma | 70 | 2020-11-02 | 2026-06-22 |
Breast Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
olaparib (2) · Azacitidine (1) · Everolimus (1) · Fulvestrant (1) · Pemetrexed (1) · abemaciclib (1) · elacestrant (1) · exemestane (1) · venetoclax (1)
United Kingdom (4) · United States (3) · Spain (2) · Australia (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Taiwan (1) · United Arab Emirates (1)
David Taussig (1)